Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2009

Open Access 01-12-2009 | Case report

Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia

Authors: Emin Alioglu, Nurullah Tuzun, Fahri Sahin, Buket Kosova, Serkan Saygi, Istemihan Tengiz, Ugur Turk, Nazan Ozsan, Ertugrul Ercan

Published in: Thrombosis Journal | Issue 1/2009

Login to get access

Abstract

A 68-year-old woman presented with acute chest pain and a greatly increased platelet count. Cardiac catheterization revealed subtotal occlusion and a thrombus-like filling defect in the right coronary artery. The patient was successfully treated with intravenous tirofiban. Essential thrombocythemia was diagnosed based on bone marrow findings, clinical presentation and laboratory analysis. The relationship between intracoronary thrombus and essential thrombocythemia is discussed.
Appendix
Available only for authorised users
Literature
1.
Spivak JL: Polycythemia vera and other myeloproliferative diseases. In Harrison's Principles of Internal Medicine. Volume 1. 14th edition. Edited by: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. The McGraw-Hill Companies, Inc., New York; 1998:683-684.
2.
Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: The 2008 WHO criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22: 14-22. 10.1038/sj.leu.2404955CrossRefPubMed
3.
Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990, 8: 556-62.PubMed
4.
Mitus AJ, Schafer AI: Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 1990, 4: 157-77.PubMed
5.
Silverstein MN: Primary or hemorrhagic thrombocythemia. Arch Intern Med 1968, 122: 18-22. 10.1001/archinte.122.1.18CrossRefPubMed
6.
Tirodo I, Fontcuberta J, Soria JM: Rapid detection of the 46C --> T polymorphism in the factor XII gene, a novel genetic risk factor for thrombosis, by melting peak analysis using fluorescence hybridization probes. Genet Test 2003, 7: 295-301. 10.1089/109065703322783644CrossRef
7.
Zhou J, Chew M, Ravn HB, Falk E: Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest (Suppl) 1999, 230: 3-11.CrossRef
8.
Tun A, Khan IA: Myocardial infarction with normal coronary arteries: the pathologic and clinical perspectives. Angiology 2001, 52: 299-304. 10.1177/000331970105200501CrossRefPubMed
9.
Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W: Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol Biol (Paris) 2007, 55(2):92-104.CrossRef
10.
Sahin F, Saydam G: Essential thrombocythemia and cardiac disorders. J Card Res 2007, 6: 116-122.
11.
Wehmeier A, Daum I, Jamin H, Schneider W: Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991, 63: 101-106. 10.1007/BF01707281CrossRefPubMed
12.
Gunes Y, Erbas C, Okuyan E, Babalik E, Gurmen T: Myocardial infarction with intracoronary thrombus induced by anabolic steroids. Anadolu Kardiyol Derg 2004, 4(4):357-8.PubMed
13.
Kralovics R, Skoda RC: Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005, 19: 1-13. 10.1016/j.blre.2004.02.002CrossRefPubMed
14.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023CrossRefPubMed
15.
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007, 21: 1658-1668. 10.1038/sj.leu.2404750CrossRefPubMed
16.
Dobrzanski P: CEP-701 Is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. Blood 2006., 108: abst. 3594.
17.
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108: 3472-6. 10.1182/blood-2006-04-018879CrossRefPubMed
18.
Borze I, Mustjoki S, Juvonen E, Knuutila S: Haematologica. 2008, 93(5):787-8.
19.
Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP: The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002, 9: 131-137. 10.1097/00043798-200204000-00009CrossRefPubMed
20.
Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002, 347: 1916-1923. 10.1056/NEJMoa021445CrossRefPubMed
21.
Sarecka B, Zak I, Krauze J: Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease. Clin Biochem 2008, in press.
22.
Böttiger C, Koch W, Lahn C, Mehilli J, von Beckerath N, Schömig A, Kastrati A: 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 2003, 146(5):855-61. 10.1016/S0002-8703(03)00363-6CrossRefPubMed
23.
Douste-Blazy P, Taudou MJ, Delay M, Pris J, Sie P, Ribaut L, Ribaut L, Galinier F, Bernadet P: Essential thrombocythaemia and recurrent myocardial infarction. Lancet 1984, 2: 992. 10.1016/S0140-6736(84)91217-0CrossRefPubMed
24.
Virmani R, Popovsky MA, Roberts WC: Thrombocytosis, coronary thrombosis and acute myocardial infarction. Am JMed 1979, 67: 498.
25.
Kaya H, Gundogdu M, Tekin SB, Akarsu E, Bozkurt E: Essential thrombocythemia and recurrent myocardial infarction. Clin Lab Haematol 2000, 22: 161. 10.1046/j.1365-2257.2000.00302.xCrossRefPubMed
26.
Esteves FA, Costa FA, Lima AA, Kajita LJ, Martinez Filho EE: Essential thrombocythemia and acute myocardial infarction treated with rescue coronary angioplasty. Arq Brasil Cardiol 1999, 73: 97.
Metadata
Title
Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia
Authors
Emin Alioglu
Nurullah Tuzun
Fahri Sahin
Buket Kosova
Serkan Saygi
Istemihan Tengiz
Ugur Turk
Nazan Ozsan
Ertugrul Ercan
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2009
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-7-1

Other articles of this Issue 1/2009

Thrombosis Journal 1/2009 Go to the issue

Original basic research

Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study

Original basic research

Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment

Editorial

Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority

Original clinical investigation

Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction

Case report

Aminaphtone in the control of Schamberg's disease

Case report

Delayed formation of pulmonary artery stump thrombus: a case report and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits